$0.80
−6.83%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.86
From 52W high−99.83%
Volume189123.00
Market cap$2.69M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.86
From 52W high
−99.83%
Volume
189123.00
Market cap
$2.69M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.4x
P/E (TTM)
—
RSI (14)
25.7
MomentumView details →
1D Return
−6.83%
YTD Return
−95.46%
SummaryUpdated Jul 1, 2026
Clearmind Medicine Inc. (NASDAQ:CMND) is a pre-clinical stage biotechnology company founded in 2017 and based in Vancouver, Canada. The company went public in November 2022 and focuses on developing novel psychedelic-based medicines to treat underserved mental health conditions. Originally incorporated as Cyntar Ventures Inc., the company changed its name to Clearmind Medicine Inc. in March 2021 to reflect its specialized focus on psychedelic therapeutics. As a pre-clinical company, Clearmind has not yet generated revenue and remains in the early stages of drug development.
Similar companies
Latest newsMore news →
Clearmind Medicine's Chief of Global Impact, Mary-Elizabeth Gifford, testified at a U.S. Food and Drug Administration hearing in Washington, D.C. on the potential future therapeutic use of psychedelic drugs, addressing patient access.3d agoClearmind Medicine delivered a briefing to the FDA after being invited to a psychedelic hearing in Washington, D.C., where its Chief of Global Impact Mary-Elizabeth Gifford spoke on patient access and shared insights from the company's clinical trial at Yale and Johns Hopkins.3d agoClearmind Medicine Inc. announced the enrollment of the first patients with Alcohol Use Disorder in its ongoing clinical trial evaluating CMND-100, its proprietary psychedelic-based treatment candidate for AUD.9d ago